Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

ward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to raise additional funds or enter strategic alliances, advance development of our potential products and complete research and development, including pre-clinical and clinical studies, the continuation of arrangements with partners and customers, competition, government regulation and approvals, and general economic conditions. For example, we may not obtain regulatory approval for our products, which would materially impair our ability to generate revenue, or we may not be able to raise capital or generate revenue to finance our operations. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

                                SCOLR Pharma, Inc.

                             CONDENSED BALANCE SHEETS

                                              June 30, 2009   December 31,
                                               (Unaudited)        2008
                                              -------------   --
'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 Mathematic ... at Harvard University , and funded by the ... aggressive cells within tumors can be visually identified for elimination. ... tumor,s growth. The study, which shows a topological map of ... needed time in cancer research, for while tumor cells can ...
(Date:8/21/2014)... KONG , Aug. 21, 2014  China Cord Blood ... announced its plan to release financial results for the ... 28, 2014, after market close in the US.  ... at 8:00 a.m. ET on Friday, August 29, 2014 ... overview of the Company,s recent developments, followed by a ...
(Date:8/21/2014)... Chester, NJ (PRWEB) August 21, 2014 ... of personal selling optimization technology and services for ... publication of “Grading Pharma’s Use of New Commercial ... of Measurement & Analytics. , The article examines ... marketing yield that are being tested in the ...
(Date:8/21/2014)... 21, 2014 Gallus BioPharmaceuticals ... development and manufacturing organization (CMO) announced today that ... an oncology company focused on the development of ... manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal ... Under the agreement the antibody will be ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... Second Quarter and Six-Month Results -- NEW YORK, Aug. 19 /PRNewswire-Asia/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... and CAMBRIDGE, Massachusetts, August 19, 2010, ... ... var shortURL ... by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... an improved coating technique that could strengthen the connection ... The stronger connection -- created by manipulating signals the ... allow the implants to last longer. Implants coated ... mimics the body,s own cell-adhesion material fibronectin made 50 ...
Cached Biology Technology:Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 2Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 3Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 4Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 5Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 6Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 7Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 8Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 9Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 10Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 11Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results 12Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 2Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 3Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 4Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 5Broad Institute Acquires License to all ChemAxon products and Deploys Across Chemical Biology Platform 6Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 2Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 3
(Date:8/21/2014)... BATON ROUGE In a finding that has implications ... and planets elsewhere in the solar system, LSU Associate ... funded by the National Science Foundation, or NSF, this ... sediments of a lake that lies 800 meters (2600 ... sheet support "viable microbial ecosystems.", Given that more than ...
(Date:8/21/2014)... in the journal Carcinogenesis by researchers at ... the protein adenomatous polyposis coli (APC) in suppressing colorectal ... the U.S. , Lead author Kristi Neufeld, associate professor ... the Cancer Biology program at the KU Cancer Center, ... to understand the various activities of APC, a protein ...
(Date:8/21/2014)... have developed a novel and versatile modeling strategy to ... new materials as well as for studying polyelectrolytes, including ... to model much larger and more complex polyelectrolyte systems, ... Li, lead author of a paper on the work ... Materials Science and Engineering. "This is a big step ...
Breaking Biology News(10 mins):800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... for superconductivity to branch out and meet some of ... according to a topical review `Superconductivity and the environment: ... journal Superconductor Science and Technology , which explains ... hospitals and address wider issues such as water purification, ...
... and Keshan disease (KD) are major endemic diseases in ... of Professor Xiong Guo from the Institute of Endemic ... of Xi,an Jiaotong University, Key Laboratory of Environment and ... of Trace Elements and Endemic Diseases of Health Ministry, ...
... to buy eco-friendly bamboo apparel are attracted if the ... novelty of the product, according to a new study ... many as friendly to the environment, although the Federal ... some pollutants are released in production from bamboo stalks., ...
Cached Biology News:Superconductivity to meet humanity's greatest challenges 2Superconductivity to meet humanity's greatest challenges 3Several common differentially expressed genes between Kashin-Beck disease and Keshan disease 2Several common differentially expressed genes between Kashin-Beck disease and Keshan disease 3Novelty of eco-friendly bamboo garments lures consumers -- if the price is right, Baylor study shows 2